CCL21 and neoplasm: Tumours associated with hypoxia are immunosuppressive and lack high expression of CCL21 and therefore therapeutic use of recombinant chemokines (such as CCL21) to stimulate immune cell recognition in tumours is being considered as a novel treatment approach (116, 117).